155 related articles for article (PubMed ID: 36179402)
1. Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase.
Robello M; Zheng H; Saha M; George Rosenker KM; Debnath S; Kumar JP; Tagad HD; Mazur SJ; Appella E; Appella DH
Eur J Med Chem; 2022 Dec; 243():114763. PubMed ID: 36179402
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.
Fujimoto H; Onishi N; Kato N; Takekawa M; Xu XZ; Kosugi A; Kondo T; Imamura M; Oishi I; Yoda A; Minami Y
Cell Death Differ; 2006 Jul; 13(7):1170-80. PubMed ID: 16311512
[TBL] [Abstract][Full Text] [Related]
4. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
5. Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.
Tagad HD; Debnath S; Clausse V; Saha M; Mazur SJ; Appella E; Appella DH
ChemMedChem; 2018 May; 13(9):894-901. PubMed ID: 29476592
[TBL] [Abstract][Full Text] [Related]
6. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.
Yamaguchi H; Durell SR; Chatterjee DK; Anderson CW; Appella E
Biochemistry; 2007 Nov; 46(44):12594-603. PubMed ID: 17939684
[TBL] [Abstract][Full Text] [Related]
7. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
[TBL] [Abstract][Full Text] [Related]
8. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.
Brazina J; Svadlenka J; Macurek L; Andera L; Hodny Z; Bartek J; Hanzlikova H
Cell Cycle; 2015; 14(3):375-87. PubMed ID: 25659035
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.
Yoda A; Xu XZ; Onishi N; Toyoshima K; Fujimoto H; Kato N; Oishi I; Kondo T; Minami Y
J Biol Chem; 2006 Aug; 281(34):24847-62. PubMed ID: 16798742
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
11. WIP1 phosphatase at the crossroads of cancer and aging.
Le Guezennec X; Bulavin DV
Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
[TBL] [Abstract][Full Text] [Related]
12. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability.
Lu X; Nguyen TA; Zhang X; Donehower LA
Cell Cycle; 2008 Jan; 7(2):164-8. PubMed ID: 18333294
[TBL] [Abstract][Full Text] [Related]
13. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
14. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
Darlington Y; Nguyen TA; Moon SH; Herron A; Rao P; Zhu C; Lu X; Donehower LA
Oncogene; 2012 Mar; 31(9):1155-65. PubMed ID: 21765465
[TBL] [Abstract][Full Text] [Related]
15. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase.
Oliva-Trastoy M; Berthonaud V; Chevalier A; Ducrot C; Marsolier-Kergoat MC; Mann C; Leteurtre F
Oncogene; 2007 Mar; 26(10):1449-58. PubMed ID: 16936775
[TBL] [Abstract][Full Text] [Related]
16. Wip1 phosphatase: between p53 and MAPK kinases pathways.
Goloudina AR; Kochetkova EY; Pospelova TV; Demidov ON
Oncotarget; 2016 May; 7(21):31563-71. PubMed ID: 26883196
[TBL] [Abstract][Full Text] [Related]
17. Loss of Wip1 sensitizes cells to stress- and DNA damage-induced apoptosis.
Xia Y; Ongusaha P; Lee SW; Liou YC
J Biol Chem; 2009 Jun; 284(26):17428-37. PubMed ID: 19395378
[TBL] [Abstract][Full Text] [Related]
18. Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.
Xu C; Minaguchi T; Qi N; Fujieda K; Suto A; Itagaki H; Shikama A; Tasaka N; Akiyama A; Nakao S; Ochi H; Satoh T
World J Surg Oncol; 2022 Apr; 20(1):139. PubMed ID: 35490254
[TBL] [Abstract][Full Text] [Related]
19. Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation.
Schito ML; Demidov ON; Saito S; Ashwell JD; Appella E
J Immunol; 2006 Apr; 176(8):4818-25. PubMed ID: 16585576
[TBL] [Abstract][Full Text] [Related]
20. A novel assay for screening WIP1 phosphatase substrates in nuclear extracts.
Storchova R; Burdova K; Palek M; Medema RH; Macurek L
FEBS J; 2021 Oct; 288(20):6035-6051. PubMed ID: 33982878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
